HeartBeam to Discuss Q4 2025 Results and Strategic Growth Initiatives in March Conference Call

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, will host a conference call at 4:30 p.m. Eastern time on March 12, 2026, to discuss its financial results for the fourth quarter and full year ended Dec. 31, 2025. The call will also provide updates on key strategic growth initiatives, including the limited commercial launch and progress on its 12-lead ECG extended wear patch. A press release detailing the results will be issued prior to the call. The company is dedicated to transforming the detection and monitoring of critical cardiac conditions by creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG.

This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, potentially redefining the future of cardiac health management. The importance of this development lies in its potential to make sophisticated cardiac monitoring more accessible and continuous, moving beyond traditional clinical settings. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement.

The limited commercial launch and progress updates to be discussed are critical as they mark the transition from regulatory approval to real-world application, testing the technology's market acceptance and clinical utility. The conference call will offer insights into the company's financial health and operational milestones, which are vital for investors and stakeholders tracking the commercialization of this innovative medical device. The cleared indications for use detail the intended application of HeartBeam's technology, and more information can be found at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.

The implications of HeartBeam's advancements extend beyond the company itself, potentially impacting the broader cardiac care landscape by enabling more proactive and remote patient management. This could lead to earlier detection of cardiac issues, reduced hospital visits, and improved patient outcomes. The scheduled conference call is therefore a significant event for monitoring the progress of a technology that aims to decentralize cardiac diagnostics. The discussion of financial results alongside strategic initiatives provides a comprehensive view of the company's trajectory as it seeks to capitalize on its FDA clearances and patented technology. The convergence of financial performance and technological deployment highlights the commercial and clinical stakes involved in bringing innovative medical devices to market.